MedPath

Study of Marham Kharish Jadeed (Unani Drug) in Ringworm

Phase 2
Completed
Conditions
Health Condition 1: null- QUBA (TINEA CORPORIS)
Registration Number
CTRI/2017/12/010995
Lead Sponsor
Central Research Institute of Unani Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
60
Inclusion Criteria

1.Patients having Quba (Tinea corporis) with the following signs and symptom:

a.Itching

b.Erythema

c.Scaling of lesion

d.Central clearing with peripheral raised margins

2.Patients with a mycological diagnosis of Tinea Corporis confirmed by microscopic KOH wet mount

Exclusion Criteria

1.All other clinical types of tinea infections

2.Patients with secondary bacterial infections/ Diabetes Mellitus

3.Pregnant and lactating women

4.Significant Pulmonary/Cardiovascular/Hepato-renal Dysfunction

5.Known cases of Immunocompromised states (HIV/ AIDS, etc.)

6.History of hypersensitivity to Terbinafine and Marham Kharish Jadeed

7.Patients using the following medications:

8.Topical antifungal agent/ topical corticosteroids in treatment area within 30 days of baseline visit

9.Systemic anti-fungals within 8 weeks of baseline visit (8 months for oral Terbinafine)

10.Systemic corticosteroids within 30 days of baseline visit

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath